Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelika Caputo

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Alzheimer'S Research & Therapy|March 6, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's diseaseAngelika Caputo, Amy Racine, Ines Paule, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b studyRik Vandenberghe, Marie-Emmanuelle Riviere, Angelika Caputo, et al.
Breast Cancer Research : BCR|April 3, 2008
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastGunter von Minckwitz, Hans-Peter Sinn, Günter Raab, et al.
Alzheimer'S Research & Therapy|May 29, 2020
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's diseaseJessica B Langbaum, Noel N Ellison, Angelika Caputo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2023
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotesMarie-Emmanuelle Riviere, Jessica B Langbaum, R Scott Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Nature Medicine|January 6, 2026
Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trialBeth Borowsky, Harry Ramos, Angelika Caputo, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 19, 2019
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's diseaseCristina Lopez Lopez, Pierre N Tariot, Angelika Caputo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 25, 2024
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation StudiesPierre N Tariot, Marie-Emmanuelle Riviere, Stephen Salloway, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Alzheimer'S Research & Therapy|March 6, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's diseaseAngelika Caputo, Amy Racine, Ines Paule, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b studyRik Vandenberghe, Marie-Emmanuelle Riviere, Angelika Caputo, et al.
Breast Cancer Research : BCR|April 3, 2008
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastGunter von Minckwitz, Hans-Peter Sinn, Günter Raab, et al.
Alzheimer'S Research & Therapy|May 29, 2020
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's diseaseJessica B Langbaum, Noel N Ellison, Angelika Caputo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2023
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotesMarie-Emmanuelle Riviere, Jessica B Langbaum, R Scott Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupGunter von Minckwitz, Günter Raab, Angelika Caputo, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Nature Medicine|January 6, 2026
Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trialBeth Borowsky, Harry Ramos, Angelika Caputo, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 19, 2019
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's diseaseCristina Lopez Lopez, Pierre N Tariot, Angelika Caputo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 25, 2024
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation StudiesPierre N Tariot, Marie-Emmanuelle Riviere, Stephen Salloway, et al.
Pageof 2